Discover
bimekizumab (UCB4940) / UCBBimekizumab phase 3 psoriasis study demonstrates superiority versus Humira (PRNewswire) - Dec 6, 2019 - P3, N=478; BE SURE (NCT03412747); Sponsor: UCB Biopharma; "UCB...announced positive results from the Phase 3 active-controlled BE SURE study. BE SURE compared...bimekizumab to the TNF inhibitor adalimumab in the treatment of adults with moderate-to-severe plaque psoriasis. BE SURE met its co-primary endpoints at week 16, demonstrating superiority of bimekizumab to adalimumab....The BE SURE study also met all of its ranked secondary endpoints with statistical significance..."ANB019 / AnaptysBioANB019 clinical trial estimate: Top-line data from P2 POPLAR trial (NCT03633396) for palmoplantar pustulosis in H1 2020 (Wedbush) - Dec 5, 2019 - A subscription to Thomson ONE is required to gain full access to report 68304667; Page no: 2, 3; REPORT TITLE: "Anaptybio Inc- D/g to Neutral; Etokimab miss disappointing, but ANAB's still better than cash"; AUTHOR: Nirengarten, David, et al; DATE: 11/08/2019Avsola (infliximab-axxq) / AmgenFDA approves Amgen's Avsola (infliximab-axxq), for the same indications as Remicade (infliximab) (Amgen Press Release) - Dec 6, 2019 - "Amgen...announced that the U.S. Food and Drug Administration (FDA) has approved AVSOLA (infliximab-axxq) for all approved indications of the reference product, Remicade (infliximab): for the treatment of moderate-to-severe rheumatoid arthritis (RA), moderate-to-severe Crohn's Disease (CD) in the adult and pediatric population, moderate-to-severe ulcerative colitis (UC) in the adult and pediatric population, chronic severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)...AVSOLA, an anti-tumor necrosis factor alpha (anti-TNF) monoclonal antibody, was proven to be highly similar to Remicade with no clinically meaningful differences based on a totality of evidence which included comparative analytical, nonclinical and clinical data."Cosentyx (secukinumab) / NovartisCosentyx: Regulatory submission for pediatric psoriasis in 2019 (Novartis) - Dec 6, 2019 - R&D Day: Regulatory submission for psoriasis in 2020; Regulatory submission for spondyloarthritis in 2022; Regulatory submission for ankylosing spondylitis beyond 2023 [Screenshot]Cosentyx (secukinumab) / NovartisCosentyx pricing: Wholesale acquisition cost of $5,179/Injection (J.P. Morgan) - Dec 6, 2019 - A subscription to Thomson ONE is required to gain full access to report 68429567; Page no: 20; REPORT TITLE: "Pharmaceuticals weekly: Weekly chartbook: TRx for week ending November 22nd and October IQVIA sales data”; AUTHOR: Vosser, Richard, et al; DATE: 12/02/2019Taltz (ixekizumab) / Eli LillyTaltz pricing: Wholesale acquisition cost of $5,162/Injection (J.P. Morgan) - Dec 6, 2019 - A subscription to Thomson ONE is required to gain full access to report 68429567; Page no: 20; REPORT TITLE: "Pharmaceuticals weekly : Weekly chartbook: TRx for week ending November 22nd and October IQVIA sales data”; AUTHOR: Vosser, Richard, et al; DATE: 12/02/2019Tremfya (guselkumab) / J&JTremfya pricing: Wholesale acquisition cost of $10,859/Injection (J.P. Morgan) - Dec 6, 2019 - A subscription to Thomson ONE is required to gain full access to report 68429567; Page no: 20; REPORT TITLE: "Pharmaceuticals weekly : Weekly chartbook: TRx for week ending November 22nd and October IQVIA sales data”; AUTHOR: Vosser, Richard, et al; DATE: 12/02/2019Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimKorea Food and Drug Administration approves moderate to severe plaque psoriasis treatment [Google Translation] (The Herald Business - Herald Corp) - Dec 4, 2019 - "The Food and Drug Administration approved the Skyrich Freefield Syringe (American Risankizumab) for severe psoriasis treatment of Abbi Korea."Otezla (apremilast) / AmgenOtezla sales projection: $1.9-2B in 2019 and $2.2B in 2020 (Jefferies) - Dec 4, 2019 - A subscription to Thomson ONE is required to gain full access to report 68384328; Page no: 1; REPORT TITLE: "Amgen Inc- Raising guidance on Otezla accretion even earlier "; AUTHOR: Yee, Michael, et al; DATE: 11/21/2019Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko KirinA Phase 4 Clinical Study of Brodalumab (clinicaltrials.gov) - Dec 3, 2019 - P4; N=138; Completed; Sponsor: Kyowa Kirin Co., Ltd.
